Clinical Question
Does the tripeptide KPV effectively modulate inflammatory pathways, specifically NF-kB, and does current evidence support its clinical utility in humans?
Evidence Snapshot
- Evidence Grade: D+
- Study Types: Preclinical only; NF-kB inhibition observed in Inflammatory Bowel Disease (IBD) models.
- Human Data: Zero human clinical trials identified.
- Safety Data: Zero FAERS safety signals reported; however, there is a lack of human pharmacokinetics or bioavailability data.
- Regulatory Status: Not FDA approved; listed as Category 2 (September 2023) due to no human exposure data.
What the Research Shows
Current research on KPV is restricted to preclinical environments. Data indicates that KPV acts as a C-terminal tripeptide fragment (Lys-Pro-Val) derived from alpha-melanocyte stimulating hormone (alpha-MSH). In laboratory models focused on Inflammatory Bowel Disease (IBD), the peptide has demonstrated the ability to inhibit NF-kB.
Notably, the research emphasizes that these effects occur without the side effects typically associated with melanocortin receptor activation. Despite these observations in models, there is no available data regarding its performance, efficacy, or safety in human subjects, as no clinical trials have been conducted to date.
Mechanism
The mechanism of KPV is centered on its interaction with cellular inflammatory signaling. According to preclinical data, the peptide inhibits the nuclear translocation of NF-kB. By preventing this translocation, KPV reduces the downstream production of pro-inflammatory cytokines. Unlike the parent molecule alpha-MSH, KPV achieves this inhibition without melanocortin receptor-mediated side effects, suggesting a specific pathway of action focused on the NF-kB transcription factor.
Limitations of the Evidence
The primary limitation of the KPV evidence base is the absolute lack of human clinical trials. There is currently no data regarding human pharmacokinetics, dosing, or systemic bioavailability. Furthermore, manufacturing and purity standards for this peptide have not been established.
From a regulatory perspective, KPV was designated as Category 2 in September 2023 because of the absence of human exposure data. Additionally, the regulatory history includes a 2020 FDA warning letter issued to Tailor Made regarding the substance. The evidence grade of D+ reflects these significant gaps, as all current findings are confined to IBD models and mechanistic laboratory studies.
Clinical Takeaway
KPV is a tripeptide fragment of alpha-MSH that demonstrates NF-kB inhibition in preclinical IBD models. While it is characterized by its ability to bypass melanocortin receptor-mediated effects, the total absence of human clinical data, lack of established manufacturing standards, and current regulatory status (Category 2) mean its clinical profile in humans remains unknown.
Sources
- TruthTides Clinical Database: KPV Profile (Grade D+).
- Regulatory Status: FDA 503a Category 2 (Sept 2023); Warning Letter (2020).
- Mechanistic Data: NF-kB inhibition in IBD models.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.